TY - JOUR T1 - Development and validation of a dissolution test for a once-a-day combination tablet of immediate-release cetirizine dihydrochloride and extended-release pseudoephedrine hydrochloride. AU - Likar,Michael D, AU - Mansour,Hany L, AU - Harwood,Jeffrey W, PY - 2005/03/07/received PY - 2005/04/28/revised PY - 2005/04/30/accepted PY - 2005/6/25/pubmed PY - 2006/1/7/medline PY - 2005/6/25/entrez SP - 543 EP - 51 JF - Journal of pharmaceutical and biomedical analysis JO - J Pharm Biomed Anal VL - 39 IS - 3-4 N2 - A dissolution test for a once daily combination tablet containing 10 mg of cetirizine dihydrochloride (cetirizine HCl) for immediate release and 240 mg of pseudoephedrine hydrochloride (pseudoephedrine HCl) for extended release was developed and validated according to current ICH and FDA guidelines. The cetirizine HCl is contained within an outer layer of the tablet while a semipermeable membrane of cellulose acetate and polyethylene glycol controls the rate at which pseudoephedrine HCl is released from the tablet core. The dissolution method, which uses USP apparatus 2 with paddles rotating at 50 rpm, 1000 ml of deaerated water as the dissolution medium, and reversed-phased HPLC for quantitation, was demonstrated to be robust, discriminating, and transferable. These test conditions were selected after it was demonstrated that the cetirizine HCl portion of the tablet rapidly dissolved in aqueous media over the physiologically relevant pH range of 1.1-7.5, and that the extended-release profile of pseudoephedrine HCl was independent of dissolution conditions (i.e., apparatus, pH, and agitation). SN - 0731-7085 UR - https://www.unboundmedicine.com/medline/citation/15975755/Development_and_validation_of_a_dissolution_test_for_a_once_a_day_combination_tablet_of_immediate_release_cetirizine_dihydrochloride_and_extended_release_pseudoephedrine_hydrochloride_ DB - PRIME DP - Unbound Medicine ER -